A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. (Q42702496)
Jump to navigation
Jump to search
scientific article published on 21 February 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. |
scientific article published on 21 February 2015 |
Statements
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis (English)
D Pariser
M Catlin
G Wierz
G Ball
B Akinlade
B Zeiher